<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062697</url>
  </required_header>
  <id_info>
    <org_study_id>EK 1148/2011</org_study_id>
    <nct_id>NCT02062697</nct_id>
  </id_info>
  <brief_title>Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.</brief_title>
  <acronym>LUDOC</acronym>
  <official_title>Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes - LUDOC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epithelial Ovarian cancer (EOC) is the leading cause of death among gynaecologic malignancies
      in western civilized countries, with an estimated prevalence in Europe and the US of 752,600
      in 2007 and 59,828 deaths annually.

      State-of-the-art diagnostic tests for EOC include transvaginal ultrasonography and serum
      cancer antigen (CA-125) measurements; the specificity of these diagnostic tools however is
      low, and both tests are not effective enough at detecting EOC early enough to improve
      clinical outcomes. Definitive diagnosis of EOC still relies on histological or cytological
      confirmation. These findings underline the importance for an effective test for early
      detection of EOC.

      In the current project we will obtain a lavage of the uterine cavity. It will be investigated
      whether cells from EOCs or genetic material from those cells can be detected in the lavage
      fluid.

      Aim of this study:

      There is a clear clinical need for a diagnosis test to detect EOC at an earlier stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epithelial Ovarian cancer is the leading cause of death among gynaecologic malignancies in
      western civilized countries, with an estimated prevalence in Europe and the US of 752,600 in
      2007 and 59,828 deaths annually. Treatment and survival of the patients depend primarily on
      the stage of the disease. Of all EOC patients only 25% are diagnosed at an early stage while
      the tumour is confined to the pelvis. In these cases the five-year survival rate is 80% to
      90% and the disease can often be cured by the combination of surgery and chemotherapy.
      Unfortunately, almost 75% of women affected have advanced stage disease with metastatic
      spread throughout the abdominal cavity or to retroperitoneal lymph nodes at the time of
      diagnosis; five-year survival rates drop to 10%-30% for advanced disease, despite maximum
      surgical effort and combination chemotherapy.

      State-of-the-art diagnostic tests for EOC include transvaginal ultrasonography and serum
      cancer antigen (CA-125) measurements; the specificity of these diagnostic tools however is
      low, and both tests are not effective enough at detecting EOC early enough to improve
      clinical outcomes. Definitive diagnosis of EOC still relies on histological or cytological
      confirmation. These findings underline the importance for an effective test for early
      detection of EOC.

      In the current project we will obtain a lavage of the uterine cavity. It will be investigated
      whether cells from EOCs or genetic material from those cells can be detected in the lavage
      fluid.

      Aim of this study:

      There is a clear clinical need for a diagnosis test to detect EOC at an earlier stage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of EOCs by mutation analysis in the lavage of the uterine cavity.</measure>
    <time_frame>Day 1</time_frame>
    <description>If the adnexal tumor removed turns out to be an EOC, mutation analysis will be carried out applying the sensitive massively parallel sequencing method published by Kinde et al. Mutations in the following genes will be analysed: AKT1, APC, ARID1A, BRAF, CTNNB1, CSMD3, CDKN2A, EGFR, FBXW7, FAT3, FGFR2, KRAS, MLL2, NRAS, PTEN, PIK3CA, PIK3R1, PPP2R1A, PIK3R, RNF43, and TP53.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of EOCs by mutation analysis of the liquid-based Pap smear.</measure>
    <time_frame>Day 1</time_frame>
    <description>Obtaining material from the uterine cervix by applying a liquid-based Pap smear technique to directly compare the two sampling techniques - Lavage and liquid-based Pap.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>Ovarian Epithelial Cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lavage of the Cavum uteri and proximal fallopian tubes
Liquid-PAP (Papanicolaou) smear</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lavage of the Cavum uteri and proximal fallopian tubes</intervention_name>
    <arm_group_label>Ovarian Epithelial Cancer</arm_group_label>
    <other_name>MF 13005 (MADICOPLAST Catheter)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liquid-PAP smear</intervention_name>
    <arm_group_label>Ovarian Epithelial Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspected ovarian cancer

          -  verified ovarian cancer

        Exclusion Criteria:

          -  pregnant

          -  incapacitated persons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Speiser, Univ.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna, Dptm. of Obstetrics &amp; Gynaecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Zeillinger, Univ.Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University Vienna, Dptm. of Obstetrics &amp; Gynaecology, Molecular Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Speiser, Univ.Prof.Dr.</last_name>
    <phone>+436765367608</phone>
    <email>paul.speiser@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina M Pecha, abs.med.</last_name>
    <phone>+436767168264</phone>
    <email>nina.pecha@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Vienna, Dptm. of Obstetrics &amp; Gynaecology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Speiser, Prof.Dr., MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven - Department of Obstetrics and Gynaecology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignace Vergote, Prof.Dr.med.</last_name>
      <phone>+32/1634</phone>
      <phone_ext>4208</phone_ext>
      <email>ignace.vergote@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Els Van Nieuwenhuysen, Dr.med.</last_name>
      <phone>+32 16 34</phone>
      <phone_ext>74 19</phone_ext>
      <email>joke.deroover@uz.kuleuven.ac.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charles University, Pilsen - Medical Faculty Hospital, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Pilsen</city>
        <state>Plzeň Region</state>
        <zip>301 66</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Bouda, M.D., Ph.D.</last_name>
      <email>boudaj@medima.cz</email>
    </contact>
    <contact_backup>
      <last_name>Alena Bartáková, M.D.</last_name>
      <email>alurge@seznam.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité University - Campus Virchow Clinic</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalid Sehouli, Prof.Dr.</last_name>
      <email>Jalid.Sehouli@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Ioana Braicu, Dr.</last_name>
      <phone>+49 30 450 564</phone>
      <phone_ext>002</phone_ext>
      <email>ioana@braicu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jalid Sehouli, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Essen Mitte (KEM)</name>
      <address>
        <city>Essen</city>
        <zip>92 45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anreas Du Bois, Prof.Dr.med.</last_name>
      <phone>+49 (0) 201 174</phone>
      <phone_ext>34002</phone_ext>
      <email>a.dubois@kliniken-essen-mitte.de</email>
    </contact>
    <contact_backup>
      <last_name>Florian Heitz, Dr.med.</last_name>
      <phone>+49 (0) 201 174</phone>
      <phone_ext>34444</phone_ext>
      <email>f.heitz@kliniken-essen-mitte.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Mahner, Priv.-Doz. Dr.med.</last_name>
      <phone>(040) 7410-23800</phone>
      <email>s.mahner@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Fabian Trillsch, Dr.med.</last_name>
      <phone>(040) 7410-23800</phone>
      <email>f.trillsch@uke.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Paul Speiser, Prof.MD,</investigator_full_name>
    <investigator_title>Univ.Prof.MD.</investigator_title>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Glandular and Epithelial</keyword>
  <keyword>Ovarian Neoplasms</keyword>
  <keyword>Ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

